[go: up one dir, main page]

ES2196026T3 - Uso de ndv en la fabricacion de un medicamento para tratar el cancer. - Google Patents

Uso de ndv en la fabricacion de un medicamento para tratar el cancer.

Info

Publication number
ES2196026T3
ES2196026T3 ES94916604T ES94916604T ES2196026T3 ES 2196026 T3 ES2196026 T3 ES 2196026T3 ES 94916604 T ES94916604 T ES 94916604T ES 94916604 T ES94916604 T ES 94916604T ES 2196026 T3 ES2196026 T3 ES 2196026T3
Authority
ES
Spain
Prior art keywords
ndv
manufacture
treat cancer
medicinal product
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94916604T
Other languages
English (en)
Inventor
Robert M Lorence
Kirk W Reichard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Biologics Corp
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of ES2196026T3 publication Critical patent/ES2196026T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION PROPORCIONA UN METODO DE TRATAMIENTO DE CANCER EN UN MAMIFERO QUE COMPRENDE LA ADMINISTRACION AL MAMIFERO DE UNA CANTIDAD EFECTIVA DE VIRUS, PARTICULARMENTE VIRUS DE LA ENFERMEDAD DE NEWCASTLE O OTROS PARAMIXOVIRUS. LA INVENCION ADEMAS PROPORCIONA UN METODO DE TRATAMIENTO DE CANCER EN UN MAMIFERO QUE COMPRENDE LA ADMINISTRACION DE TALES VIRUS AL MAMIFERO EN COMBINACION CON OTRO AGENTE COMO UN COMPUESTO QUIMIOTERAPEUTICO, INMUNOADYUVANTE, CITOQUINA O AGENTE INMUNOSUPRESOR. LA INVENCION PROPORCIONA ADEMAS UN METODO DE DETECCION DE CELULAS CANCERIGENAS EN UN MAMIFERO UTILIZANDO PARAMIXOVIRUS COMO UN AGENTE DE PRESENTACION Y COMO UN INDICADOR DEL CRECIMIENTO DE CELULAS CANCERIGENAS EN EL MAMIFERO.
ES94916604T 1993-04-30 1994-04-29 Uso de ndv en la fabricacion de un medicamento para tratar el cancer. Expired - Lifetime ES2196026T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5551993A 1993-04-30 1993-04-30

Publications (1)

Publication Number Publication Date
ES2196026T3 true ES2196026T3 (es) 2003-12-16

Family

ID=21998395

Family Applications (3)

Application Number Title Priority Date Filing Date
ES94916604T Expired - Lifetime ES2196026T3 (es) 1993-04-30 1994-04-29 Uso de ndv en la fabricacion de un medicamento para tratar el cancer.
ES02026340T Expired - Lifetime ES2310580T3 (es) 1993-04-30 1994-04-29 Composiciones purificadas del virus de la enfermedad de newcastle.
ES04017349T Expired - Lifetime ES2315595T3 (es) 1993-04-30 1994-04-29 Composiciones para tratar cancer con uso de virus.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES02026340T Expired - Lifetime ES2310580T3 (es) 1993-04-30 1994-04-29 Composiciones purificadas del virus de la enfermedad de newcastle.
ES04017349T Expired - Lifetime ES2315595T3 (es) 1993-04-30 1994-04-29 Composiciones para tratar cancer con uso de virus.

Country Status (12)

Country Link
US (2) US7056689B1 (es)
EP (4) EP2009119A1 (es)
JP (3) JP4338781B2 (es)
AT (3) ATE401092T1 (es)
AU (1) AU699487B2 (es)
CA (1) CA2161671A1 (es)
DE (3) DE69435118D1 (es)
DK (3) DK1314431T3 (es)
ES (3) ES2196026T3 (es)
HK (1) HK1052871A1 (es)
PT (3) PT1486211E (es)
WO (1) WO1994025627A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1486211E (pt) * 1993-04-30 2009-02-02 Wellstat Biologics Corp Composições para tratamento do cancro utilizando vírus
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
NZ518945A (en) 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
FR2788099B1 (fr) 1999-01-06 2001-02-09 Vallourec Mannesmann Oil & Gas Assemblage filete de deux tubes metalliques a couple eleve de vissage
AU2005201079C1 (en) * 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
AU4246900A (en) * 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
WO2002000233A2 (en) 2000-06-26 2002-01-03 Wellstat Biologics Corporation Purging of cells using viruses
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
DE60239394D1 (de) 2001-05-11 2011-04-21 Wellstat Biologics Corp Onkolytische virustherapie
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7615209B2 (en) * 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
RU2314830C2 (ru) * 2002-06-21 2008-01-20 Веллстат Байолоджикс Корпорейшн Введение терапевтических вирусов
EP1578451A4 (en) * 2002-11-05 2007-01-24 Wellstat Biologics Corp TREATMENT OF CARCINOID TUMORS WITH THERAPEUTIC VIRUSES
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
NZ543056A (en) * 2003-03-24 2008-04-30 Wellstat Biologics Corp Newcastle disease virus comprising a plurality of doses for treating a mammalian subject having a tumour
JPWO2005042737A1 (ja) * 2003-11-04 2007-05-10 株式会社ディナベック研究所 遺伝子導入された樹状細胞の製造方法
US20060018884A1 (en) * 2003-11-25 2006-01-26 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
NZ550430A (en) * 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
CA2571849A1 (en) * 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having rna virus transferred thereinto
MX2007015407A (es) * 2005-07-14 2008-02-19 Wellstat Biologics Corp Tratamiento del cancer utilizando virus, fluoropirimidinas y camptotecinas.
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
US20090175826A1 (en) * 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
ES2532808T3 (es) 2008-09-16 2015-03-31 Genomidea Inc. Agente terapéutico/profiláctico para cáncer de próstata
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
MD4655C1 (ro) 2013-03-14 2020-06-30 Icahn School Of Medicine At Mount Sinai Virusurile bolii de Newcastle şi utilizarea acestora
US20170000832A1 (en) 2014-02-27 2017-01-05 Viralytics Limited Combination method for treatment of cancer
CA3026892A1 (en) 2017-05-10 2018-11-15 Wellstat Immunotherapeutics, Llc Enveloped virus resistant to complement inactivation for the treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577525A (en) 1964-07-01 1971-05-04 Cornell Res Foundation Inc Adenovirus vaccine against canine hepatitis
NL7111160A (es) 1971-03-09 1972-09-12
ZA754725B (en) 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
JPS5173117A (en) * 1974-12-19 1976-06-24 Handai Biseibutsubyo Kenkyukai Ganryohozaino seiho
US4108983A (en) 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
US4126671A (en) 1976-08-17 1978-11-21 Pitman-Moore, Inc. Method for detecting bovine leukemia viral infection
US4379839A (en) 1977-05-23 1983-04-12 The Trustees Of Columbia University In The City Of New York Method for detecting cancer
IT1117218B (it) 1979-05-18 1986-02-17 Depa Sas Procedimento per la produzione di un prodotto per la diagnosi dei tumori delle parti molli o carcinomi e prodotto ottenuto
US4282315A (en) 1979-09-13 1981-08-04 Corning Glass Works Preparation of enriched whole virus radioligand
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4465769A (en) 1981-12-11 1984-08-14 The United States Of America As Represented By The Department Of Health And Human Services Non-transformed thymidine kinaseless cell line and its use for testing tumorigenic potential of genes
JPS58116422A (ja) 1981-12-28 1983-07-11 Green Cross Corp:The 抗腫瘍剤
US4582787A (en) 1982-12-30 1986-04-15 Frankel Jack W Method of testing a patient for a predisposition to lung cancer, certain other cancers, neurofibromatosis and certain other hereditary disorders
US4571385A (en) 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
JPS6089755A (ja) 1983-07-01 1985-05-20 フイリツプ・ジヨン・ベア−ド 診断用試薬及びその製造法並びにそれを用いる診断法
US4647773A (en) 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS60249058A (ja) 1984-05-25 1985-12-09 Eisai Co Ltd Ａｔｌウイルス抗体の測定方法および試薬
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
US5075213A (en) 1984-07-27 1991-12-24 City Of Hope Method for detection and prevention of human cytomegalovirus infection
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
FR2593828B2 (fr) 1986-01-31 1990-05-04 Pasteur Institut Sonde a papillomavirus et procede de diagnostic in-vitro d'infections a papillomavirus
US4735895A (en) 1984-12-28 1988-04-05 Oncotech, Inc. Cancer susceptibility test
GB8500918D0 (en) 1985-01-15 1985-02-20 Cancer Res Inst Viral isolates
US4786590A (en) 1985-01-15 1988-11-22 California Institute Of Technology Diagnostic and therapeutic aspects of receptor-mediated leukemogenesis
US4970071A (en) 1985-01-18 1990-11-13 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
EP0252940A4 (en) 1985-12-05 1989-07-27 Hutchinson Fred Cancer Res Anti-sense rna for treatment of retroviral disease states.
AU602875B2 (en) 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4861720A (en) 1986-07-03 1989-08-29 Regents Of The University Of California Oncornavirus vaccines and feline alpha-type interferon
NZ224567A (en) * 1987-05-19 1990-08-28 Yissum Res Dev Co Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
US4849334A (en) 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4908306A (en) 1987-06-12 1990-03-13 Life Technologies, Inc. Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
DE3722968A1 (de) 1987-07-11 1989-01-19 Behringwerke Ag Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine
CA1341439C (en) 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
DE68929343T2 (de) 1988-02-16 2002-09-12 Greatbatch Gen-Aid, Ltd. Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5077198A (en) 1988-04-14 1991-12-31 Eastman Kodak Company Diagnostic kit and method for rapid detection of antibodies
US5124148A (en) 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5215745A (en) 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
FR2632956B2 (fr) 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5057314A (en) 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
FR2639225B1 (fr) 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
US5169753A (en) 1989-06-05 1992-12-08 Genelabs Incorporated Method and kit for detecting human retrovirus
FR2656627B1 (fr) 1989-12-28 1992-04-17 Pasteur Institut Sonde a papillomavirus (hvpv63), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus.
CN1054192A (zh) * 1990-02-26 1991-09-04 张炳团 人体内诱导干扰素的制造方法
US5739107A (en) * 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5195539A (en) * 1992-03-23 1993-03-23 Minnesota Mining And Manufacturing Company Earplug compression device
WO1993018790A1 (en) 1992-03-24 1993-09-30 Csatary Laszlo K Vaccine containing live virus for therapy of viral diseases and malignancies
PT931830E (pt) 1993-02-16 2001-08-30 Onyx Pharma Inc Virus citopaticos para terapia e profilaxia de neoplasia
JPH08508641A (ja) 1993-03-16 1996-09-17 ブリテイツシユ・テクノロジー・グループ・リミテツド ウイルスタンパク質による免疫応答刺激
PT1486211E (pt) * 1993-04-30 2009-02-02 Wellstat Biologics Corp Composições para tratamento do cancro utilizando vírus
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
EP1578451A4 (en) * 2002-11-05 2007-01-24 Wellstat Biologics Corp TREATMENT OF CARCINOID TUMORS WITH THERAPEUTIC VIRUSES

Also Published As

Publication number Publication date
WO1994025627A1 (en) 1994-11-10
JP2005187484A (ja) 2005-07-14
EP1486211B1 (en) 2008-10-22
DK1486211T3 (da) 2009-01-19
EP2009119A1 (en) 2008-12-31
AU699487B2 (en) 1998-12-03
AU6821394A (en) 1994-11-21
ATE401092T1 (de) 2008-08-15
DK1314431T3 (da) 2008-11-10
EP1486211A1 (en) 2004-12-15
PT1314431E (pt) 2008-10-24
CA2161671A1 (en) 1994-11-10
HK1052871A1 (en) 2003-10-03
ES2315595T3 (es) 2009-04-01
DE69435118D1 (de) 2008-08-28
ATE236271T1 (de) 2003-04-15
DE69432409T2 (de) 2003-12-24
EP1314431B1 (en) 2008-07-16
JPH09503995A (ja) 1997-04-22
DE69435155D1 (de) 2008-12-04
PT696326E (pt) 2003-08-29
EP0696326B1 (en) 2003-04-02
EP1314431A3 (en) 2003-06-18
EP0696326A4 (en) 1997-08-20
DE69432409D1 (de) 2003-05-08
US7736640B2 (en) 2010-06-15
PT1486211E (pt) 2009-02-02
US20060216310A1 (en) 2006-09-28
DK0696326T5 (da) 2003-07-14
JP2009149689A (ja) 2009-07-09
US7056689B1 (en) 2006-06-06
ATE411809T1 (de) 2008-11-15
EP1314431A2 (en) 2003-05-28
DK0696326T3 (da) 2003-06-23
EP0696326A1 (en) 1996-02-14
JP4338781B2 (ja) 2009-10-07
ES2310580T3 (es) 2009-01-16

Similar Documents

Publication Publication Date Title
ES2196026T3 (es) Uso de ndv en la fabricacion de un medicamento para tratar el cancer.
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
DE69811062D1 (de) Polyaromatische antivirale zusammensetzungen
MX9203396A (es) Monohidrato de furoato de mometasona, proceso para producirlo y composiciones farmaceuticas.
DE69430611D1 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
DK0392300T3 (da) Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
ATE91233T1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
MX9306012A (es) Formulaciones novedosas para agentes de contraste radiograficos ennanoparticulas para la coleccion sanguinea utilizando surfactantes noionicos de elevado peso molecular.
AR003119A1 (es) Composicion farmaceutica para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres que comprenden una mezcla de un n- clorofenilcarbamato o un n- clorofeniltiocarbamato y un n- fosfonoglicina y uso de dicha composicion farmaceutica para la manufactura de un medicamento para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
EA200000978A1 (ru) Противоопухолевая композиция, содержащая синергическую комбинацию производного антрациклина и производного камптотецина
ATE205881T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
AR002987A1 (es) Composicion farmaceutica para el tratamiento de infecciones virales ocanceres o tumores, composicion de dosis unitaria que la comprende y uso para dicho tratamiento
IL117874A0 (en) Pharmaceutical compositions for inhibiting the growth of viruses and cancers
DE69915977D1 (de) Neuartige Heparin bindende Peptide
DE69123363D1 (de) Neue zusammensetzungen
BR9106272A (pt) Composicoes farmaceuticas contendo ipriflavona,processo para sua preparacao e uso terapeutico relativo
BR9202709A (pt) Composicao,processo para aperfeicoar as propriedades de uso de lubrificantes e compostos
NO913502L (no) Kompositt for anvendelse som hoeyenergi-sprengstoff eller drivmiddel.
BR9812002A (pt) Compostos com efeito antiprimeiro-passe
BR9106596A (pt) Processo para o tratamento ou profilaxia de uma infeccao associada com retrovirus,uso,composicao farmaceutica para o tratamento ou profilaxia de uma infeccao associada com retrovirus,e,composto
ATE47863T1 (de) Makrolide derivate.
MX9401370A (es) Terapia antiviral.
ECSP941089A (es) Agentes arilantes
ES2086395T3 (es) Fosfolipidos para el tratamiento de esclerosis multiple.